Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.

Journal Article (Journal Article)

BACKGROUND: Some drugs for irritable bowel syndrome (IBS) have serious side effects. AIMS: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure. METHODS: We collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV-defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables. RESULTS: Participants would accept a median 2.0% (IQR 0.0%-9.0%) risk of death in return for a 98.0% (IQR 91.0%-100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom-specific anxiety (P < 0.001 for trend), and lower IBS-related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores. CONCLUSION: Patients are willing to accept significant risks in return for cure of their IBS symptoms.

Full Text

Duke Authors

Cited Authors

  • Goodoory, VC; Ng, CE; Black, CJ; Ford, AC

Published Date

  • May 2022

Published In

Volume / Issue

  • 55 / 10

Start / End Page

  • 1311 - 1319

PubMed ID

  • 35166374

Pubmed Central ID

  • PMC9303338

Electronic International Standard Serial Number (EISSN)

  • 1365-2036

Digital Object Identifier (DOI)

  • 10.1111/apt.16816


  • eng

Conference Location

  • England